ADDISON, Texas (PRWEB) July 18, 2013
OsteoMed received FDA 510K approval on June 5, 2013, to sell and market ExtremiFuse™ for the correction of Hammertoe deformity.
“Our commitment to providing improved patient outcomes through the design, manufacture and service of high quality, innovative and cost-effective surgical products continues with this exciting new product offering,” stated David Kelly, Vice President of OsteoMed’s Small Bone Orthopedic Division.
ExtremiFuse™ offers an exceptional solution to address a prevalent clinical problem, while saving time in the operating room for surgeons and the patients they treat. There is an estimated 60 million people that suffer from Hammertoe deformities in the U.S., according to iData Research. There are roughly 550,000 surgeries performed on an annual basis to correct this painful deformity, which is most prevalent in the second, third and fourth toes.
The ExtremiFuse™ Hammertoe implant integrates OsteoMed’s established screw technology with an innovative quad barb design. ExtremiFuse™ offers the surgeon several clinical advantages over existing available options to assure ease of use and correct clinical placement; including cannulated implants and offering ExtremiFuse™ in both a straight and 10 degree solution. This provides intra-operative clinical options for optimal desired results. These self-drilling, threaded implants provide for easy insertion—they can be placed without using a drill and it reduces the force need to fully place the implant. ExtremiFuse™ is OsteoMed’s latest product release and will complement the existing comprehensive lower extremity product portfolio.
For more information about ExtremiFuse™, visit the OsteoMed website.
OsteoMed was founded in 1990 with the principle mission of improving patient outcomes through the development of advanced medical devices. Working in close collaboration with leading surgeons to create patient-focused solutions, OsteoMed services the Small Bone Orthopedics, Craniomaxillofacial, Neuro, and Spine surgical specialties. Each business unit has dedicated resources to assure focus on addressing unmet clinical needs that are unique to each surgical specialty.
More information on OsteoMed, the Small Bone Orthopedic Business Unit and ExtremiFuse™ can be found at http://www.osteomed.com.
Read the full story at http://www.prweb.com/releases/OsteoMed/ExtremiFuse-hammertoe/prweb10943369.htm.
Copyright©2012 Vocus, Inc.
All rights reserved